An interventional study of Lispro and Lispro in Diabetes Mellitus, Type 1, sponsored by Manchester University NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-10-31.
Sponsored by Manchester University NHS Foundation Trust · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.
Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 48th largest by planned enrollment, is one of 2 that started in 2023, is one of 13 with no phase, and was the 65th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 7–18
Tel-Aviv Sourasky Medical Center · Sites in Israel
Ages 18+
By country, each count listing its studies:
Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 9 · Phase 3 14 · Phase 4 12
First in 2002; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 26 is below the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 38 across the 69 interventional studies. Of the 60 that completed or were terminated, 33 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 69 have an industry lead sponsor. The 10 most frequent:
Manchester University NHS Foundation Trust is the lead sponsor of 140 studies on the registry; 27 are open to participants now.
Manchester University NHS Foundation Trust has 8 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
1 of the studies testing Insulin Lispro in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of the study is to determine whether fully closed-loop insulin delivery using ultra-rapid acting insulin lispro will improve glucose control compared to standard lispro under conditions mimicking missed meal bolus. Ultra-rapid acting lispro (Lyumjev) is a novel formulation of insulin lispro in which two additional excipients (citrate and trepostinil) have been added, resulting in accelerated initial absorption and more than double the glucose lowering effect in the first 30 minutes after subcutaneous administration using insulin pump. To date, no randomised controlled trial involving fully closed-loop in type 1 diabetes has been performed to evaluate the benefit of Lyumjev over standard lispro.
This is an open-label, single-centre, two-period, randomised, crossover study. The study involves two 12-hour in-patient stays at the clinical research facility during which glucose levels will be controlled by the Cambridge closed-loop system with either Lyumjev or standard lispro. Up to 26 adults with type 1 diabetes treated with insulin pump will be recruited at Manchester Royal Infirmary, aiming for 19 completed participants.
During the study days, closed-loop will automatically modulate insulin infusion rate based on real-time glucose sensor measurements. Participants will receive standardised meals with no meal bolus for the lunch time meal during each study day. Primary outcome is the time spent in sensor glucose range (3.9-10.0mmol/l) between 11:00 - 17:00 hrs. Secondary outcomes are the time spent with glucose levels above and below target, and other sensor-based metrics. Safety evaluation comprises assessment of the frequency of hypo and hyperglycaemic episodes.
Study Design An open-label, single-centre, randomised, 2-period cross-over study, in adults (18 years and older) with type 1 diabetes on insulin pump treatment.
It is expected that up to 26 adults with type 1 diabetes will be recruited, aiming for 19 completed participants. The study flow chart is outlined in Figure 2.
Study Subjects Study Population This is a single centre study and recruitment will take place at the Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust. Up to a total of 26 adults aged 18 years and older with type 1 diabetes on insulin pump therapy will be recruited aiming for 19 completed participants. Potential participants will be identified by their treating clinicians and invited to contact the research team. They will be sent the study information leaflets and an invitation to join the study by the research team.
Randomisation Eligible subjects will be randomised by the clinical researcher up to 14 days prior to first in-patient stay using Sealed Envelope randomisation software to undertake closed-loop studies in one of two possible random sequences; ultrarapid-acting lispro followed by insulin lispro, or insulin lispro followed by ultrarapid-acting insulin lispro.
Study Schedule Overview The study will be co-ordinated from the Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester. The study will consist of five Visits including two 9-hour stays at the MCRF, Manchester Royal Infirmary, Manchester. Visits 1 and 2 may be combined. Tables 1 and 2 summarise the study visits.
Recruitment Visit and Baseline Assessment (Visit 1)
Once the subjects have agreed to participate in the study, they will be invited for the recruitment visit, when the following activities will be performed by the research team:
Training Session on Continuous Glucose Monitoring (Visit 2) This session will cover key aspects of the study CGM and attention will be paid to the following areas. This visit could be combined with visit 1.
Written easy to use guidelines for the operation of CGM device will be provided. This session will be conducted by a professional pump educator / study nurse and possibly a member of the study team. Competency on the use of CGM will be assessed and additional training will be provided if deemed necessary by the Competency Assessment Form.
Visit 3 - Optimisation During Visit 3, after a 2 to 3 weeks' run-in period, glucose control will be optimised, if required, by the study team with special focus on insulin to carbohydrate ratios.
Manchester Diabetes Centre is the largest insulin pump centre in UK. We expect most of the participants in the study to be already well optimised. However, we will ensure this further by reviewing insulin, glucose and carbohydrate data during the two-week run-in period. Particular attention will be on the insulin carbohydrate ratio to see whether it is over aggressive. If the insulin to carb ratio is over aggressive this could potentially reduce the difference between Lispro and Lyumjev during the study. Participants whose glucose levels drops (those who develop hypoglycaemia within 2 to 3 hours of meal bolus) carb ratio will be adjusted to avoid this drop. Participants will also be randomised at visit 3.
Visit 4 will follow within 2 weeks of Visit 3. Participants will be advised to avoid strenuous exercise 24 hours prior to each in-patient stay to avoid any bias arising from changes in insulin sensitivity.
Activities during 9-hour in-patient stay (Visits 4 and 5, Figure 3) There will be two in-patient study days, performed within 1-6 weeks of each other. On each Study Day, participants will arrive at the study centre at approximately 08.30 and will be discharged by 18.00 the same day.
Participants will be advised to insert a new CGM sensor 48 hours before the planned admission. A new insulin infusion cannula will be inserted on admission to the clinical research facility. In addition, participant will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin lispro, this will be changed to ultra rapid-acting lispro 24-hour prior to the admission for closed loop with ultrarapid-acting lispro and vice versa.) Participants will be requested to fast from 12 midnight prior to admission (carbohydrate-free liquids are allowed). Participants will be requested to check their glucose between 05:00 and 07:00. If the glucose level is, or anticipated to be, \< 4 mmol/l during this period, additional carbohydrate can be taken to aim for arrival glucose between 4 and 10 mmols. Correction insulin doses may be given if arrival glucose is anticipated to be above range (>10 mmol/l). Study visits may be rescheduled if participants develop significant hypoglycaemia (\<3.0 mmol) or significant hyperglycaemia (glucose >20 mmol/l and/or ketones >0.6 mmol/l) 6 hours prior to or on arrival. On arrival, participant's usual insulin pump will be changed to study insulin pump. Closed-loop with either ultrarapid-acting lispro or insulin lispro will commence between 09:00 and 17:00 hours.
A 60g meal will be served at 11:00 with no meal bolus to mimic a missed meal bolus.
The study will end at 17.00. Patients will be switched back to their usual insulin pump therapy at the end of the study. Standard operating procedures will be in place for treatment of hypo and hyperglycaemia. Figure 3 summarises activities during the 9 hour in-patient stay.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ultrarapid-acting lispro delivered by hybrid closed loop system.
Drug: Lispro
Insulin lispro delivered by hybrid closed loop system.
Drug: Lispro
Ultra rapid Lispro
Also known as: Lyumjev
Conventional Lispro
Also known as: Humalog
Time in range
The primary outcome is time spent in the target glucose range (3.9 to 10.0 mmol/l) based on sensor glucose levels, between the hours of 11:00 and 17:00 hours, during inpatient stay
Time frame: 6 hours
Area under curve
• Incremental area above the curve of sensor glucose level during the first 4 hours after the meal.
Time frame: 4 hours
Time below target
Time spent below target glucose (\<3.9mmol/l)
Time frame: 6 Hours
Time above target
Time spent abovetarget glucose (10.0mmol/l)
Time frame: 6 Hours
Mean glucose and glycaemic variability
Average, coefficient of variation and standard deviation glucose levels
Time frame: 6 hours
Insulin dose
Total, basal and bolus insulin dose
Time frame: 6 hours
Time above and below significant sensor glucose levels
The time with sensor glucose levels \< 3.5 mmol/l, 3.0 and \<2.8 mmol/l and the time with sensor glucose levels in the significant hyperglycaemia (glucose levels \> 16.7 mmol/l)
Time frame: 6 hours
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for May 2024, 9 months after the start.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 9 months is below that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Lispro
Manchester University NHS Foundation Trust →